BioAtla Inc (NASDAQ: BCAB) is a clinical-stage biopharmaceutical company that develops conditionally active biologics, a class of antibody-based therapeutics designed to be active in the tumor microenvironment. The company has no approved products and generates no product revenue, funding operations entirely through equity and financing arrangements. As of the 10-K filed March 31, 2026, BioAtla reported a net loss of $59.6 million for the year ended December 31, 2025, and net cash used in operating activities of $48.2 million for that same period. The company entered into a Standby Equity Purchase Agreement (SEPA) and Pre-Paid Advance agreements (PPAs) announced in November 2025 as financing mechanisms. BioAtla has never declared or paid cash dividends. An Agreement and Plan of Merger was announced January 30, 2026, with an amendment filed March 2, 2026, signaling a potential acquisition or restructuring event. Competitors hold substantially greater financial resources and development capabilities, per the company's own 10-K disclosure.

Revenue model

BioAtla has no product revenue as of FY2025. The company funds operations through equity financing, including a Standby Equity Purchase Agreement and Pre-Paid Advance agreements announced in November 2025. Net loss was $59.6 million for the year ended December 31, 2025.

Products and services

BioAtla's pipeline consists of conditionally active biologic (CAB) antibody-based product candidates targeting oncology indications. The filing references companion diagnostic development alongside its therapeutic candidates. No products have received marketing approval as of the 10-K filed March 31, 2026.

Customers and end markets

Target end market is oncology, with product candidates intended for cancer patients. No commercial customers exist as of the filing date. Reimbursement from Medicare, Medicaid, and third-party payors is cited as a material factor for future product competitiveness.

Value-chain role

BioAtla operates as a drug discovery and clinical development company. It relies on contract research organizations (CROs) and third-party manufacturers for preclinical and clinical activities. It does not manufacture or commercialize products as of the 10-K filed March 31, 2026.

Geographic exposure

The filing references the FDA and EMA as relevant regulatory authorities, indicating U.S. and potential European development activity. No specific geographic revenue breakdown is disclosed, consistent with pre-revenue status.

Source: SEC 10-K, filed 2026-03-31

Industry: Biological Products, (No Diagnostic Substances) Peers: Arbutus Biopharma Corp AVEO PHARMACEUTICALS, INC. Vaxart Inc Tango Therapeutics Inc GreenLight Biosciences Holdings, PBC Sutro Biopharma Inc Generation Bio Co. Immuneering Corp Poseida Therapeutics, Inc.